Gene therapy for restenosis.
This review provides an overview of candidate genes that are currently being evaluated for genetic strategies in vascular gene therapy. We discuss treatment strategies that have proven efficacious in limiting postinterventional restenosis through evaluation with in vivo model systems. The candidate strategies utilize genes that are either cytotoxic, regulate vascular smooth muscle cell differentiation or proliferation. In addition, we review oligonuclotide and ribozyme strategies that function by suppressing the expression of cell cycle regulators.
Smith
R C
RC
Division of Cardiovascular Research, St. Elizabeth's Medical Center, 736 Cambridge Street, Boston, MA 02135, USA.
Walsh
K
K
D000818:Animals; D019485:Bone Morphogenetic Proteins / Q000502:physiology; D018797:Cell Cycle Proteins; D002455:Cell Division; D002465:Cell Movement; D003327:Coronary Disease / Q000503:physiopathology / Q000628:therapy*; D015536:Down-Regulation; D018507:Gene Expression Regulation, Developmental; D005801:Genes, Homeobox; D018816:Genes, cdc; D015316:Genetic Therapy; D006801:Humans; D009131:Muscle, Smooth, Vascular / Q000166:cytology; D019001:Nitric Oxide Synthase / Q000235:genetics; D016376:Oligonucleotides, Antisense / Q000627:therapeutic use; D010641:Phenotype; D012008:Recurrence; D014158:Transcription, Genetic
D019485:Bone Morphogenetic Proteins; D018797:Cell Cycle Proteins; D016376:Oligonucleotides, Antisense; D019001:Nitric Oxide Synthase